| アブストラクト | Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat obesity and diabetes but are linked to a variety of gastrointestinal (GI) adverse events (AEs). Real-world data on GLP-1 RA-related GI AEs and outcomes are limited. This study assessed GI AEs and adverse outcomes using the US FDA Adverse Event Reporting System (FAERS). Methods: This retrospective pharmacovigilance study used the US FDA FAERS database (2007-2023). We searched GLP-1 RA medications, AEs, and adverse outcomes. Demographic, treatment indication, and AE data were collected. Descriptive analysis involved frequencies and percentages, while reporting odds ratio (ROR), proportional reporting ratio, Bayesian confidence propagation neural network, and multivariate logistic regression were used to analyze GLP-1 RA-related GI AEs and outcomes. Results: From 2007 to 2023, a total of 187,757 AEs were reported with GLP-1 RAs, and 16,568 were GLP-1 RA-associated GI AEs in the US. Semaglutide was linked to higher odds of nausea (IC(025): 0.151, beta(Coeff): 0.314), vomiting (IC(025): 0.334, beta(Coeff): 0.495), and delayed gastric emptying (IC(025): 0.342, beta(Coeff): 0.453). Exenatide was associated with pancreatitis (IC(025): 0.601, beta(Coeff): 0.851) and death (ROR: 4.50, IC(025): 1.101). Overall, semaglutide had a broader range of notable adverse effects; by comparison, dulaglutide and liraglutide use was associated with fewer significant GI AEs. Conclusions: Analysis of the FAERS data reveals that GLP-1 RAs, particularly semaglutide and exenatide, are significantly associated with specific GI AEs, such as nausea, vomiting, delayed gastric emptying, and pancreatitis. Clinicians should be aware of these potential risks to ensure optimal monitoring and patient safety. This study demonstrated the utility of pharmacovigilance data in identifying safety signals, which can inform future pharmacoepidemiological investigations to confirm causal relationships. Clinicians should be aware of these potential risks to ensure optimal monitoring and patient safety. |
|---|
| ジャーナル名 | Diagnostics (Basel, Switzerland) |
|---|
| Pubmed追加日 | 2025/1/8 |
|---|
| 投稿者 | Osei, Samuel Prince; Akomaning, Edwin; Florut, Teodora Francesca; Sodhi, Mohit; Lacy, Brian E; Aldhaleei, Wafa A; Bhagavathula, Akshaya Srikanth |
|---|
| 組織名 | Department of Public Health, North Dakota State University, Fargo, ND 58108, USA.;Faculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.;Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z1,;Canada.;Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL 32224,;USA.;Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39767190/ |
|---|
